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The lung clearance index (LCI) measured by multiple breath washout (MBW) is accepted as a surrogate endpoint for clinical trials (1) and may be a useful test to clinically monitor lung function in children and adults with cystic fibrosis (CF). The review of evidence for the use of LCI in CF clinical trials published in 2014 concluded that LCI has good clinimetric properties including strong intra-test repeatability, strong correlation with validated measure of lung function (FEV1), quality of life and pulmonary exacerbation in both child and adult groups (2) .
LCI is responsive to modulator therapy and is predictive of future lung function (1, 3) . In health, the longitudinal evolution of LCI declines from infancy to early childhood, stabilises in early childhood to adulthood and slowly increases thereafter with age (4). The 2014 review concluded that LCI has a low variability between repeated sessions (i.e. stable coefficient of variation [CV%]) with one study reporting a coefficient of reproducibility (COR) of 0.96 for measurements 24 hours apart (using MBN2W and an Exhalyzer D a ) (5) . There have been more limited data on the longer term inter-test repeatability within the CF population, thus the interpretation of a clinically meaningful change is more difficult. Determination of the intertest repeatability is very important to inform the treatment effect that can be considered clinically significant (i.e. larger than the difference in LCI seen between repeat measurements without intervention or change in clinical status). Recent published data may go some way to address these gaps in the literature (Table 1) .
Using MBWSF6 methodology, the COR of repeated measurements approximately 8 months apart was 1.40 (6, 7) . Using MBN2W the % difference between repeated measurements ranging from 3 to 12 months apart, ranged from 17-25% with an average COR of 2.00, with good agreement reported between the 2 most recent publications in the current issue of JCF (Green et al and Svedberg et al) (3, (8) (9) (10) . Significantly, some studies (using MBN2W) indicate that LCI variability is driven by disease state (8,10) with increasing LCI variability as the LCI value increases (both within and between session). This evidence supports expressing LCI variability as a relative and not an actual change and has implications for powering a study to detect a change in LCI, i.e. base the sample size on the meaningful change expected for that disease severity.
It is also now established that the differences between MBW methodologies must be considered when interpreting the study results. In vivo and in vitro studies have demonstrated significant differences between results derived from different MBN2W devices and when different tracer gases are applied. Differences in results from different MBN2W devices are driven by the measurement algorithms used in the software results. Therefore, results are not interchangeable until there is harmonisation of measurement algorithms (11) .
On comparing the different tracer gas methods, MBN2W overestimates FRC and there is clear bias towards disproportionately higher LCI at higher mean values of LCI (i.e. more severe disease) compared with MBWSF6 (12, 13) . Importantly, there is also evidence to show that tissue N2 contribution impacts on washout, causing error in indirect measurement of N2 which is more pronounced in longer washouts (i.e. patients with higher LCI values) (13, 14) . This evidence may provide some explanation for the greater inter-test variability seen in MBN2W tests compared with SF6.
Whilst there is greater inter-test variability seen in LCI using MBN2W, the relative change in LCI was comparable to that seen in FEV1 % predicted (10) . Furthermore, intervisit repeatability data for MBWSF6 is limited to one study and further research is needed, particularly where MBN2W with 100% O2 is not a suitable approach in the infant age range.
Decreased permeation in poorly ventilated lungs may also be a potential limitation of MBWSF6 methodology which also requires further study (12) . Relating to MBN2W, further study of the impact of the application of N2 tissue excretion corrections, the use of earlier test end-points and the use of using end-tidal concentrations versus volume averaged phase III expired concentrations to identify the LCI end-point, may reduce variability and improve agreement between results from different devices using different inert gases.
To facilitate such comparisons, future studies could describe inter-visit repeatability as a percentage change, in addition to a statistic (e.g. %CV, the intra-class correlation coefficient (ICC), the limits of agreement (LOA) from Bland-Altman plots, or COR); with caution using those where it is assumed that the measurement variability is independent of its magnitude (LOA and COR).
The differences between results from MBW technologies complicate the transition of MBW from the research setting to clinical care and necessitate standardisation of specific devices and protocols for multicentre use. Feasibility data summarised in 2014 review indicated variable success rates with MBW testing ranging from 24% to 100%. Not surprisingly, most challenges have been encountered in the infant and pre-school age range due to issues relating to patient co-operation, the requirement for patient interface adjustment, a sedation protocol and the associated logistics (2) . Assessment of the most recent feasibility data in CF (Table 1) Some key questions that remain concern a clear definition of the patient subgroup where MBW would be indicated (i.e. where LCI would offer additional information to routine 
